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Interleukins are low molecular
weight proteins produced by
leukocytes that bind to cell
surface receptors and act in an
autocrine and/or paracrine
fashion. These secreted factors
modify the cell differentiation
program (survival, proliferation,
maturation, induction of or
protection from apoptosis) of the
target cells to which they bind. As
such, interleukins impact on
diverse biological processes:
tissue growth and repair,
hematopoietic homeostasis, and
at multiple levels of the host
defense against pathogens. It is
therefore not surprising that the
rather generic designation
‘interleukin’ does not refer to a
homogeneous family of proteins,
but instead to groups of proteins
that adopt different three-
dimensional structures, bind to
distinct classes of receptors, and
initiate unique signal transduction
pathways. Our discussion of
interleukins will be structured
according to the two main classes
of receptors to which they bind:
the type I and type II cytokine
receptor families and the IL-
1R/TLR (interleukin-1 receptor/
Toll-like receptor) superfamily.
Type I and II cytokine receptor
families
Type I cytokine receptors are
transmembrane proteins with four
conserved cysteine residues and a
Trp-Ser-X-Trp-Ser (WSXWS) motif
in their extracellular domain, and a
cytoplasmic tail containing
consensus motifs (‘boxes’ 1 and 2)
involved in signal transduction.
The type II cytokine receptors are
related but lack the extracellular
WSXWS motif (Table 1). Ligands
for these receptors belong to a
family characterized by the
presence of four α helices. One
predominant characteristic of the
type I and II cytokine receptor
superfamily is the utilization of
shared cytokine receptor subunits
– a single receptor chain may
participate in the generation of the
functional receptor complex for
multiple different ligands. As such,
the superfamily can be subdivided
into receptors sharing the common
β chain, the common γ chain, the
gp130 molecule, the IL-20Rβ chain
and the IL-22Rα chain (see Table
1). In addition, a number of
receptor chains are shared by two
different ligand-binding receptor
complexes: the IL-4Rα, the IL-7Rα,
the IL-12Rβ1, the IL-10Rβ and the
IL-20Rα chain.
Receptor subunit oligo-
merization plays an essential role
in signaling via the type I and II
cytokine receptors. The activation
of multiple, distinct intracellular
cascades has been documented
following type I and II cytokine
receptor oligomerization, including
the MAPK (mitogen-activated
protein kinase, also known as ERK
for extracellular-signal-regulated
kinase) cascade, the JAK/STAT
pathway (Janus kinase/signal
transducer and activator of
transcription), and the PI3-K
(phosphoinositide 3-kinase)
cascade. The JAK/STAT pathway
appears uniquely coupled to type I
and II cytokine receptor signaling,
and has been the subject of
considerable analysis: the current
model is depicted in Figure 1.
Homodimerization, hetero-
dimerization or heterotrimerization
of receptor chains in the presence
of ligand (Table 1) generates a
signaling-proficient complex,
which brings together the
receptor-bound JAKs. JAK
Table 1. The type I and II cytokine receptors.
Type Ligands Receptor JAK STAT Inhibitora
I γc-dependent: γc + ligand-specific 1,3 5,3 CIS (IL-2), 
IL-2, 7, 9, receptor chain, except SOCS1 (IL-2), 
15, 21 IL-2R and IL-15R which SOCS3 (IL-2,9)
use IL-2Rβ plus a 
specific α-chainb
IL-4 Type I IL-4R, γc + 1,3 6 SOCS1,3
IL-4Rα ; type II IL-4R, 
IL-4Rα + IL-13Rα
βc-dependent: βc + ligand-specific 2 5 CIS (IL-3), 
IL-3, 5, GM-CSF receptor chain, SOCS1 (IL-3), 
only βc binds JAK SOCS3 (IL-3)
gp130-dependent: 1,2,Tyk2 3 SOCS1,2 (IL-6,LIF), 
IL-6, 11, OSM, SOCS3 (IL-6,11,LIF)
CNTF, LIF, CT-1
IL-12 (p35/p40) IL-12Rβ1, IL-12Rβ2 2,Tyk2 4
IL-23 (p19/p40) IL-12Rβ1 ? 4
IL-27 (p28/EBI3) WSX-1
TSLP TSLPR, IL-7Rα – 5 SOCS1
GH GHR homodimer 2 5 CIS, SOCS1,2,3
EPO EPOR homodimer 2 5 CIS, SOCS3
TPO TPOR homodimer 2 5 SOCS1,3
Prolactin PRLR homodimer 2 5 CIS, SOCS1,3
Leptin Leptin receptor 2 3 SOCS3
homodimer
G-CSF G-CSFR homodimer 2 3 (1,5)
II IFNα/β IFNα/βRα, β 1,Tyk2 1,2 SOCS1
IFNγ IFNγRα, β 1,2 1 SOCS1,3
IL-10 IL-10Rα, IL-10Rβ 1,Tyk2 3 ND
IL-22 (IL-TIF) IL-22Rα, IL-10Rβ ? 1,3,5 ND
IL-20 IL-22Rα, IL-20Rβ ? 3 ND
IL-20Rα, IL-20Rβ
IL-24 (MDA-7) IL-22Rα, IL-20Rβ
IL-20Rα, IL-20Rβ ? 3 ND
IL-19 IL-20Rα, IL-20Rβ ? 3 ND
The list includes the functional receptors for a given cytokine as well as the JAK/STAT mol-
ecules activated via the receptor. aPhosphatases and PIAS not taken into account. bIL-2Rα
and IL-15Rα are not type I cytokine receptor chains. 
GM-CSF, granulocyte/monocyte-colony-stimulating factor; TSLP, thymic stroma-derived lym-
phopoietin; OSM, oncostatin M; CNTF, ciliary neurotrophic factor; LIF, leukemia inhibitory
factor; CT, cardiotrophin; GH, growth hormone; EPO, erythropoietin; TPO, thrombopoietin;
IFN, interferon; γc, common cytokine receptor gamma chain; βc, common cytokine receptor
beta chain; IL-TIF, interleukin-10-related T-cell-derived inducible factor; MDA, melanoma dif-
ferentiation-associated antigen; ND, not described.
autophosphorylation, as well as
receptor tyrosine phosphorylation
(Figure 1) generates specific
docking sites for adaptor proteins
containing Src homology 2 (SH2)
domains or phosphotyrosine-
binding (PTB) domains for
building an intracellular signaling
scaffold. STAT proteins bind to
the receptor via SH2 domains,
and themselves become tyrosine
phosphorylated. The
phosphorylated STAT proteins
then dissociate from the receptor,
homodimerize or heterodimerize
(again via their SH2 domains), and
translocate into the nucleus where
they stimulate target gene
transcription (Figure 1).
Four JAKs (JAK1, JAK2, JAK3
and Tyk2) and six STAT proteins
(STAT1–6) have been identified in
mammalian cells. Curiously, no
simple rules apply to the
utilization of the different JAKs
and STATs with different
receptors. Involvement of different
JAK and STAT proteins in signal
transduction pathways from type I
and II cytokine receptors may be
highly specific or promiscuous
(Table 1).
As mentioned above, the
JAK/STAT pathway is an
important, but by no means the
only, signal transduction pathway
triggered by type I and II cytokine
receptors. Recruitment of SH2- or
PTB-domain adaptors to the
phosphorylated receptor chains
can result in the activation of the
MAPK and the PI3-K pathways
(Figure 1). The adaptor molecule
Grb2 plays a major role in initiating
the MAPK cascade. Upon receptor
binding, Grb2 recruits, via its
amino-terminal SH3 domain, the
guanine nucleotide exchange
factor Sos to the plasma
membrane where it activates the
GTPase Ras, which in turn
activates MAPK/ERK, via several
intermediate kinases. Activation of
the MAPK/ERK pathway is not
specific to the type I and II
cytokine receptors and the
substrates of the activated MAPKs
are diverse, including transcription
factors and other kinases.
The MAPK cascade is just one
of several pathways involved in
signaling from Grb2. While the
amino-terminal SH3 domain of
Grb2 binds to Sos, its carboxy-
terminal SH3 domain recruits,
probably at the same time, the
Gab1 or Gab2 adaptor proteins.
These proteins are phosphoryl-
ated and serve as docking sites
for other proteins, such as the p85
subunit of PI3-K, the
phosphorylation of which leads to
the activation of the  protein
kinase B (PKB) pathway (Figure 1).
Some cytokine receptors, for
example IL-7Rα, have direct
binding sites for the SH2 domain
of the p85 subunit of PI3-K,
thereby allowing direct stimulation
of this specific pathway.
Scaffolding proteins like Shc also
bind to phosphorylated receptor
chains and become
phosphorylated. Shc can recruit
multiple Grb2 proteins thereby
organizing and potentiating the
signals by the activated receptor;
in this way, adaptors serve as a
core for building multiple signaling
pathways in parallel.
The regulation of signaling
through type I and II cytokine
receptors occurs at multiple levels:
soluble forms of ligand-binding
receptor subunits may act to
sequester extracellular ligands
under some conditions;
competition for shared receptor
subunits can decrease the
efficiency of signaling; and tyrosine
phosphatases (including SHP-1,
SHP-2, and CD45) may act to
dampen formation or stability of
intracellular signaling complexes. 
Suppressor of cytokine signaling
(SOCS) proteins are a family of
molecules that can bind activated
JAKs or phosphorylated receptor
chains and thereby impede
docking of STATs and/or adaptor
molecules. Different SOCS
proteins are induced by different
cytokines. The SOCS family
includes eight members: cytokine-
inducible SH2-domain-containing
protein (CIS) and SOCS1–7, which
all contain a protein motif
designated the SOCS box, also
found in a number of proteins
unrelated to cytokine signaling.
A different family of inhibitors —
protein inhibitors of activated STAT
(PIAS) — has been recently
described to bind activated STAT
proteins and prevent their
dimerization (Figure 1).
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Figure 1. Signal transduction via type I and type II cytokine
receptors. (A) Ligand-induced oligomerisation of receptor sub-
units leads to receptor phosphorylation thereby recruiting Shc
and STAT proteins. (B) Pathways of Shc-mediated PKB and
MAPK activation and STAT-induced SOCS/CIS/PIAS inhibition.
See text for details.
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The IL-1R/TLR superfamily
Recent discoveries within the
IL-1/IL-1R family provide a
dynamic example of how rapidly
the field of interleukin research is
moving. Until recently, IL-1Rs
were grouped in the family of Ig
(immunoglobulin-like)-domain
containing receptors on the basis
of the fact that they contain three
extracellular Ig domains. With the
characterization of the Toll
receptors, it became clear that a
new superfamily could be defined,
based on a homologous
cytoplasmic sequence — the
Toll/IL-1R (TIR) domain — found
not only in the Toll receptors, but
also in the IL-1R. 
The TIR-containing IL-1R/TLR
superfamily comprises three main
subgroups: the IL-1R/IL-18R
subfamily with their characteristic
extracellular Ig-domains; the Toll
receptor family, whose members
possess an extracellular leucine-
rich repeat (LRR); and a group of
cytoplasmic proteins (for example,
the signaling molecule MyD88).
As this review deals with
interleukin signaling, we will only
briefly consider the pathways
described for the mammalian
IL-1R/IL-18R receptor family. IL-1
and IL-18 are pro-inflammatory
cytokines and are important
mediators in the activation of the
innate immune system. The term
IL-1 actually refers to two different
molecules, IL-1α and IL-1β, which
have only 27% sequence identity
at the DNA level. However, as they
adopt very similar three-
dimensional structures and bind
to the same receptors, they have
almost identical biological
activities. Both IL-1 and IL-18 are
generated as precursors, which
are converted into mature forms
by caspase-1-mediated
proteolytic cleavage. IL-1β and IL-
18 are only active as mature
proteins, while IL-1α is also active
as a precursor. The binding of IL-1
to IL-1R1 is not sufficient for
signaling; only after recruitment of
IL-1RAcP (IL-1R accessory
protein, homologous to IL-1R1) is
the receptor complex signaling
proficient. IL-1R
heterodimerisation leads to the
recruitment of MyD88 (Figure 2). 
Subsequently, a (probably)
preformed complex consisting of
the recently discovered Toll-
interacting protein (TOLLIP),
IL-1R-associated kinase (IRAK)
and IRAK4 is somehow recruited
to the IL-1R–MyD88 receptor
complex. The C2 domain of
TOLLIP is believed to interact
with membrane lipids and may
play a role in the assembly of the
signaling complex (Figure 2).
Alternatively, since MyD88, IRAK
and IRAK4 each contain a death
domain (DD), the proximity of
these molecules at the receptor
may allow for their interaction
through death domain association
(Figure 2). Whatever the
mechanism, signaling involves
IRAK–IRAK4
autophosphorylation, its release
from the receptor complex and its
binding to TNF receptor
associated factor 6 (TRAF6;
Figure 2). TRAF6 in turn activates
the MAPKKKs TAK1 and MKK6
and results eventually in the
activation of NFκB and the
MAPKs, JNK and p38 (Figure 2).
IL-1 function can be regulated
at multiple levels: ligand
expression, and by modifying
signaling through the IL-1R1 (such
as by phosphatases). In addition,
IL-1 function is regulated by two
distinct mechanisms at the level
of the cell surface receptor: via
the IL-1 receptor antagonist
(IL-1ra), which inhibits recruitment
of IL-1RcAP; and via a ‘decoy’
receptor, IL-1R2, which binds IL-1
and recruits IL-1RAcP but does
not initiate a signal transduction
cascade due to its failure to
recruit MyD88. IL-1R2 can also be
proteolytically cleaved and
subsequently sequester IL-1 in
soluble form.
The structure and the signaling
of the IL-18/IL-18R system are
very similar to the IL-1/IL-1R
system. IL-18 binds to IL-18R
(also known as IL-1R-related
protein 1), which then recruits the
IL-18RAP (IL-18R accessory
protein, also known as accessory
protein-like). As the signaling
through IL-18R appears to involve
the same molecules as described
above for IL-1R, it is not surprising
that IL-18 evokes similar
biological responses as IL-1.
Regulation of the IL-18/IL-18R
system also occurs through
binding of IL-18 by IL-18BP (IL-18
binding protein).
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Figure 2. Signal transduction via the IL-1 receptor. (A) Building of
the signaling-proficient receptor–ligand complex consisting of IL-
1, IL-1R1 and IL-1RAcP allows for the recruitment of MyD88 via
the TIR domain. (B) Recruitment of the TOLLIP–IRAK–IRAK4
complex to the receptor. (C) Autophosphorylation and subsequent
dissociation of IRAK–IRAK4. (D) Binding of TRAF6 by
IRAK–IRAK4. (E) TRAF6-mediated activation of NF-κB and MAPK,
probably via TAK1 and MKK6, respectively. See text for details.
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Reconciling signaling pathways
with biological responses
The term ‘cytokine redundancy’
describes the in vitro observations
that diverse cytokines may elicit
similar biological effects on
responding target cells. Two
observations regarding interleukin
signaling appear relevant to this
concept: first, receptor subunit
sharing between distinct cytokine
receptors (common β, common γ,
gp130) provides an obvious
mechanism to generate parallel
intracellular signals. Second,
different subfamilies of cytokine
receptors can initiate similar or
identical signal transduction
pathways (PI3-K, MAPK). It is also
apparent that a given cytokine
receptor is capable of converting
a ligand-binding event into
different signal transduction
pathways. This second
characteristic of cytokine receptor
signaling may provide clues to
understanding ‘cytokine
pleiotropy’, which describes the
capacity of single cytokines to
elicit multiple biological effects.
While these proposed molecular
mechanisms provide reasonable
replies to the questions of
cytokine redundancy and
pleiotropy, there are some
reported observations which
suggest that interleukin signal
integration may be more complex.
Mutational analysis of cytokine
receptor chains has identified
regions critical for certain
biological responses in vitro; for
example, STAT activation was
found to be essential for cell
proliferation induced by IL-2 or
growth hormone or prolactin,
whereas mutations affecting
docking of other adaptors had
little effect. In contrast, use of
pharmacological agents
demonstrated that interleukin-
induced lymphocyte proliferation
is sensitive to selective inhibition
of the p38 MAPK pathway. Thus
the paradigm ‘single pathway –
single response’ may be an
oversimplification, especially if
certain biological responses
require integrative activation
across multiple pathways.
‘Crosstalk’ refers to the capacity
of individual signaling pathways to
influence each other, and
probably allows for the fine tuning
of the biological response(s) to
interleukins.
If one interleukin can initiate
different signal transduction
pathways, including their
crosstalk, which pathways are
activated under physiological
conditions and what dictates the
type of signal generated? The
answers to this question concern
‘availability’, ‘context’ and the
‘nature of the signal’. Availability
means that in order to relay a
signal through a specific pathway,
certain conditions must be met
(such as necessary adaptor
proteins must expressed, docking
sites for the adaptor proteins
must be accessible, potential
second messengers must be
present in a certain concentration
and so on). Context characterizes
the state of the cell (immature or
mature, naive or memory,
activated or resting) that is about
to respond to a given ligand as
well as the nature of other signals
perceived by that cell at the same
time. Lastly, ‘nature of the signal’
signifies the strength and duration
of the signal: a short exposure to
a certain stimulus may allow the
receptor to relay the signal to only
one pathway, while a prolonged
exposure may culminate in the
activation of several pathways. Of
course, these different conditions
have to be considered as a whole
and not as unrelated entities.
There are examples where
certain biological endpoints
appear clearly associated with
activation of specific signaling
events. Cell survival induced by
interleukins utilizing the common γ
chain appear to act via induction
and/or stabilization of expression
of Bcl-2 family members.
Curiously, this does not appear to
be the case for survival signals
induced through receptors with
intrinsic tyrosine kinase activity
(c-kit, Flk2/Flt3). It is not evident
why two distinct classes of
cytokine receptors use divergent
mechanisms to achieve a similar
biological effect.
Additional questions in the
biology of interleukin signaling
remain unanswered. Multiple
distinct cytokines have been
shown to elicit similar in vitro
biological responses in target
cells — what is the physiological
significance of this cytokine
redundancy? This is an important
question, since the concept of
cytokine redundancy evolved
largely from in vitro studies. In
contrast, clear cases of cytokine
redundancy in vivo are lacking.
Moreover, while some cytokines
may appear to act in a redundant
fashion, this does not necessarily
demonstrate that all of the
biological effects of these
different cytokines are redundant.
We favor the notion that the in
vivo role for interleukins is highly
specific and much more restricted
than suggested by previous in
vitro studies. With continued
generation of mice carrying
conditional mutations in
interleukins and their receptors,
the true biological roles for these
families of molecules should be
revealed. These discoveries will
have an important impact on the
use of interleukins under diverse
clinical conditions, including
autoimmunity, immunodeficiency
and for modulating immune
responses against pathogens.
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